These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 21138843)

  • 41. Conformational Destabilization of Immunoglobulin G Increases the Low pH Binding Affinity with the Neonatal Fc Receptor.
    Walters BT; Jensen PF; Larraillet V; Lin K; Patapoff T; Schlothauer T; Rand KD; Zhang J
    J Biol Chem; 2016 Jan; 291(4):1817-1825. PubMed ID: 26627822
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics.
    Ying T; Chen W; Feng Y; Wang Y; Gong R; Dimitrov DS
    J Biol Chem; 2013 Aug; 288(35):25154-25164. PubMed ID: 23867459
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells.
    Goebl NA; Babbey CM; Datta-Mannan A; Witcher DR; Wroblewski VJ; Dunn KW
    Mol Biol Cell; 2008 Dec; 19(12):5490-505. PubMed ID: 18843053
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics.
    Andersen JT; Sandlie I
    Drug Metab Pharmacokinet; 2009; 24(4):318-32. PubMed ID: 19745559
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
    Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
    J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Site-selective conjugation of an anticoagulant aptamer to recombinant albumins and maintenance of neonatal Fc receptor binding.
    Schmøkel J; Voldum A; Tsakiridou G; Kuhlmann M; Cameron J; Sørensen ES; Wengel J; Howard KA
    Nanotechnology; 2017 May; 28(20):204004. PubMed ID: 28362634
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A strategy for bacterial production of a soluble functional human neonatal Fc receptor.
    Andersen JT; Justesen S; Berntzen G; Michaelsen TE; Lauvrak V; Fleckenstein B; Buus S; Sandlie I
    J Immunol Methods; 2008 Feb; 331(1-2):39-49. PubMed ID: 18155020
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Endogenous IgG-based affinity-controlled release of TRAIL exerts superior antitumor effects.
    Yang H; Feng Y; Cai H; Jia D; Li H; Tao Z; Zhong Y; Li Z; Shi Q; Wan L; Li L; Lu X
    Theranostics; 2018; 8(9):2459-2476. PubMed ID: 29721092
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mechanism of increased clearance of glycated albumin by proximal tubule cells.
    Wagner MC; Myslinski J; Pratap S; Flores B; Rhodes G; Campos-Bilderback SB; Sandoval RM; Kumar S; Patel M; Ashish ; Molitoris BA
    Am J Physiol Renal Physiol; 2016 May; 310(10):F1089-102. PubMed ID: 26887834
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monovalent IgG4 molecules: immunoglobulin Fc mutations that result in a monomeric structure.
    Wilkinson IC; Fowler SB; Machiesky L; Miller K; Hayes DB; Adib M; Her C; Borrok MJ; Tsui P; Burrell M; Corkill DJ; Witt S; Lowe DC; Webster CI
    MAbs; 2013; 5(3):406-17. PubMed ID: 23567207
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design and biological evaluation of novel long-acting adalimumab Fab conjugated with the albumin binding domain.
    Zhang Q; Qian M; Wu Y; Wang Y; Shangguan W; Lu J; Zhao W; Feng J
    Eur J Pharmacol; 2021 Aug; 904():174152. PubMed ID: 33964292
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The multiple facets of FcRn in immunity.
    Stapleton NM; Einarsdóttir HK; Stemerding AM; Vidarsson G
    Immunol Rev; 2015 Nov; 268(1):253-68. PubMed ID: 26497526
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Glucagon-like Peptide 1 Conjugated to Recombinant Human Serum Albumin Variants with Modified Neonatal Fc Receptor Binding Properties. Impact on Molecular Structure and Half-Life.
    Bukrinski JT; Sønderby P; Antunes F; Andersen B; Schmidt EGW; Peters GHJ; Harris P
    Biochemistry; 2017 Sep; 56(36):4860-4870. PubMed ID: 28799326
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies.
    Wang W; Vlasak J; Li Y; Pristatsky P; Fang Y; Pittman T; Roman J; Wang Y; Prueksaritanont T; Ionescu R
    Mol Immunol; 2011 Mar; 48(6-7):860-6. PubMed ID: 21256596
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FcRn: the neonatal Fc receptor comes of age.
    Roopenian DC; Akilesh S
    Nat Rev Immunol; 2007 Sep; 7(9):715-25. PubMed ID: 17703228
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.
    Burvenich IJ; Farrugia W; Lee FT; Catimel B; Liu Z; Makris D; Cao D; O'Keefe GJ; Brechbiel MW; King D; Spirkoska V; Allan LC; Ramsland PA; Scott AM
    MAbs; 2016; 8(4):775-86. PubMed ID: 27030023
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The neonatal Fc receptor: Key to homeostasic control of IgG and IgG-related biopharmaceuticals.
    Baldwin WM; Valujskikh A; Fairchild RL
    Am J Transplant; 2019 Jul; 19(7):1881-1887. PubMed ID: 30903736
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
    Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
    MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin.
    Andersen JT; Dee Qian J; Sandlie I
    Eur J Immunol; 2006 Nov; 36(11):3044-51. PubMed ID: 17048273
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Associations between an IgG3 polymorphism in the binding domain for FcRn, transplacental transfer of malaria-specific IgG3, and protection against Plasmodium falciparum malaria during infancy: A birth cohort study in Benin.
    Dechavanne C; Dechavanne S; Sadissou I; Lokossou AG; Alvarado F; Dambrun M; Moutairou K; Courtin D; Nuel G; Garcia A; Migot-Nabias F; King CL
    PLoS Med; 2017 Oct; 14(10):e1002403. PubMed ID: 28991911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.